Accuray Stock Price, News & Analysis (NASDAQ:ARAY)

$4.85 -0.05 (-1.02 %)
(As of 12/12/2017 10:42 AM ET)
Previous Close$4.90
Today's Range$4.80 - $5.00
52-Week Range$3.60 - $6.00
Volume764,300 shs
Average Volume719,758 shs
Market Capitalization$411.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28

About Accuray (NASDAQ:ARAY)

Accuray logoAccuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Receive ARAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ARAY
CUSIP00439710
Phone408-716-4600

Debt

Debt-to-Equity Ratio2.44%
Current Ratio1.48%
Quick Ratio0.92%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$383.41 million
Price / Sales1.06
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book8.66

Profitability

Trailing EPS($0.34)
Net Income$-29,570,000.00
Net Margins-7.49%
Return on Equity-55.18%
Return on Assets-6.33%

Miscellaneous

Employees944
Outstanding Shares83,920,000

Accuray (NASDAQ:ARAY) Frequently Asked Questions

What is Accuray's stock symbol?

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) released its quarterly earnings data on Tuesday, October, 24th. The medical equipment provider reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02. The medical equipment provider earned $91 million during the quarter, compared to the consensus estimate of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. Accuray's quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the business posted ($0.12) EPS. View Accuray's Earnings History.

When will Accuray make its next earnings announcement?

Accuray is scheduled to release their next quarterly earnings announcement on Tuesday, January, 30th 2018. View Earnings Estimates for Accuray.

Where is Accuray's stock going? Where will Accuray's stock price be in 2017?

7 brokerages have issued 12-month price targets for Accuray's stock. Their predictions range from $5.00 to $10.00. On average, they anticipate Accuray's share price to reach $7.17 in the next year. View Analyst Ratings for Accuray.

What are Wall Street analysts saying about Accuray stock?

Here are some recent quotes from research analysts about Accuray stock:

  • 1. According to Zacks Investment Research, "Over the past year, Accuray has underperformed the broader industry with respect to price. Notably, the company issued solid fiscal 2018 guidance in the last quarter. Of the recent developments, orders for the latest Radixact System, solid revenue performance in APAC and Japanese regulatory approval for Radixact deserve a mention. Growing adoption of non-surgical treatment options among cancer patients, increasing demand for Accuray’s latest offerings, successful execution of restructuring plans and accretive acquisitions are other positives. Accuray’s significant international presence helps broaden its customer base. However, fluctuations in currency exchange rates, particularly with a strong dollar, will continue to adversely impact the company’s backlog and top line. Furthermore, unfavorable product mix, declining service revenues, sluggish macro economic conditions and pricing headwinds are major concerns." (10/25/2017)
  • 2. BTIG Research analysts commented, "Results: In-Line Revenue with Soft Net Orders; Neutral ARAY’s results the past few years seem to reflect a company hampered by its positioning with low market share, missed guidance, delays by the Chinese government and a tough capital structure that is trying to do all that it can to reaccelerate growth. Our concern is that continued single digit growth with lumpy orders and some quarterly revenue misses just doesn’t excite investors and we are not sure what will accelerate growth meaningfully. We applaud new product innovation and focus on consistent results. With guidance reset earlier in the year, ARAY reported in-line rev but the conversion from orders has taken longer than expected with some geographic softness. ARAY is attempting to increase growth through multiple new products such as Radixact, OnRad, Precision Treatment Planning, and iDMS Data Management. We believe this may help but at the end of the day past execution keeps us at Neutral. FY18 guidance calls for revenue of $390M – $400M (2% – 4%) and gross order growth of 5%. Both seem reasonable but also not layups. We will continue to watch for more consistency and stronger growth that would bring investors back into the story." (8/24/2017)
  • 3. Aegis analysts commented, "The company has been successful in shifting gears to the smaller vault centers, re-positioning TomoTherapy as a work horse machine. Accuray has moved outside of the niche high-end large academic centers into the broader single- and dual-vault centers, with single- and dual-vault centers now accounting for 50% of new TomoTherapy orders (up from 0% in 2012).He added, "Radixact, the next-generation TomoTherapy platform, was approved for 510k in June (CE Mark in Aug) and brings ARAY up to par with Varian's TrueBeam and Elekta's Axesse machines. Radixact adds higher output dosing along with integrated treatment planning (Precision') and data management (iDMS') systems that will increase the ease and speed of systems, and should have its full launch in time for ARAYs first major replacement cycle. The reliability issues previously associated with TomoTherapy are now behind them, and Tomo is consistantly ranked #1 in overall system performance by ServiceTrak." (2/6/2017)

Are investors shorting Accuray?

Accuray saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 7,005,156 shares, an increase of 22.6% from the November 15th total of 5,714,788 shares. Based on an average daily trading volume, of 1,399,568 shares, the days-to-cover ratio is presently 5.0 days. Approximately 8.7% of the shares of the company are sold short.

Who are some of Accuray's key competitors?

Who are Accuray's key executives?

Accuray's management team includes the folowing people:

  • Louis J. Lavigne Jr., Independent Chairperson of the Board (Age 69)
  • Joshua H. Levine, President, Chief Executive Officer, Director (Age 53)
  • Elizabeth H. Davila, Independent Vice Chairperson of the Board (Age 73)
  • Kevin Waters, Chief Financial Officer, Senior Vice President (Age 40)
  • Alaleh Nouri, Senior Vice President, General Counsel, Corporate Secretary (Age 38)
  • Lionel Hadjadjeba, Senior Vice President, Chief Commercial Officer (Age 58)
  • Andy Kirkpatrick, Senior Vice President - Global Operations (Age 54)
  • Shig Hamamatsu, Vice President, Finance and Chief Accounting Officer, Principal Accounting Officer
  • Jack Goldstein Ph.D., Independent Director (Age 70)
  • Richard R. Pettingill, Independent Director (Age 69)

Who owns Accuray stock?

Accuray's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Neuberger Berman Group LLC (6.28%), Vident Investment Advisory LLC (5.84%), Heartland Advisors Inc. (3.50%), Boston Partners (2.74%), Lapides Asset Management LLC (2.34%) and Russell Investments Group Ltd. (1.19%). Company insiders that own Accuray stock include Alaleh Nouri, Joshua Levine, Kelly Londy and Kevin Waters. View Institutional Ownership Trends for Accuray.

Who sold Accuray stock? Who is selling Accuray stock?

Accuray's stock was sold by a variety of institutional investors in the last quarter, including Lapides Asset Management LLC, Dimensional Fund Advisors LP, Heartland Advisors Inc., Schwab Charles Investment Management Inc., California State Teachers Retirement System and Cowen Prime Services LLC. Company insiders that have sold Accuray company stock in the last year include Alaleh Nouri, Joshua Levine, Kelly Londy and Kevin Waters. View Insider Buying and Selling for Accuray.

Who bought Accuray stock? Who is buying Accuray stock?

Accuray's stock was bought by a variety of institutional investors in the last quarter, including Vident Investment Advisory LLC, Neuberger Berman Group LLC, Boston Partners, Global X MANAGEMENT CO LLC, Russell Investments Group Ltd., Sectoral Asset Management Inc, Dynamic Technology Lab Private Ltd and Wells Fargo & Company MN. View Insider Buying and Selling for Accuray.

How do I buy Accuray stock?

Shares of Accuray can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Accuray's stock price today?

One share of Accuray stock can currently be purchased for approximately $4.85.

How big of a company is Accuray?

Accuray has a market capitalization of $411.20 million and generates $383.41 million in revenue each year. The medical equipment provider earns $-29,570,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Accuray employs 944 workers across the globe.

How can I contact Accuray?

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]


MarketBeat Community Rating for Accuray (ARAY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Accuray (NASDAQ:ARAY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.29$7.57$7.57$8.07
Price Target Upside: 40.11% upside66.41% upside84.67% upside77.39% upside

Accuray (NASDAQ:ARAY) Consensus Price Target History

Price Target History for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ:ARAY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2017Lake Street CapitalInitiated CoverageBuy -> Buy$10.00HighView Rating Details
10/27/2017CowenReiterated RatingBuy$9.00N/AView Rating Details
8/24/2017BTIG ResearchReiterated RatingHoldMediumView Rating Details
8/24/2017Royal Bank of CanadaReiterated RatingHold$5.00LowView Rating Details
8/23/2017Jefferies GroupLower Price TargetBuy$7.00 -> $6.00LowView Rating Details
3/21/2017AegisReiterated RatingBuyMediumView Rating Details
12/14/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$8.00 -> $6.00N/AView Rating Details
8/18/2016Morgan StanleySet Price TargetHold$8.00N/AView Rating Details
5/22/2016Brean CapitalReiterated RatingBuy$12.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Accuray (NASDAQ:ARAY) Earnings History and Estimates Chart

Earnings by Quarter for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ ARAY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/29/2018($0.08)N/AView Earnings Details
10/24/2017Q1 2018($0.09)($0.07)$88.26 million$91.00 millionViewN/AView Earnings Details
8/22/20176/30/2017($0.01)($0.06)$112.00 million$112.09 millionViewN/AView Earnings Details
4/27/2017Q3 2017$0.01($0.06)$110.23 million$97.31 millionViewN/AView Earnings Details
1/31/2017Q217($0.09)($0.11)$93.74 million$87.50 millionViewListenView Earnings Details
10/27/2016Q117($0.10)($0.12)$37.34 million$86.50 millionViewListenView Earnings Details
8/17/2016Q316($0.07)($0.09)$98.97 million$95.00 millionViewListenView Earnings Details
4/26/2016Q316($0.06)$0.01$102.79 million$105.30 millionViewListenView Earnings Details
1/28/2016Q216($0.08)($0.08)$101.15 million$108.90 millionViewListenView Earnings Details
10/29/2015Q116($0.14)($0.12)$88.60 million$89.60 millionViewListenView Earnings Details
8/20/2015Q415($0.04)($0.07)$102.41 million$101.80 millionViewListenView Earnings Details
4/30/2015Q315($0.06)($0.04)$102.72 million$97.50 millionViewListenView Earnings Details
1/27/2015Q215($0.08)($0.13)$98.87 million$98.20 millionViewListenView Earnings Details
10/29/2014Q115($0.13)($0.28)$88.90 million$82.40 millionViewListenView Earnings Details
8/21/2014Q414($0.07)($0.13)$92.23 million$102.00 millionViewListenView Earnings Details
4/30/2014Q314($0.16)($0.06)$82.00 million$97.10 millionViewListenView Earnings Details
1/30/2014Q214($0.20)($0.07)$80.20 million$93.60 millionViewListenView Earnings Details
11/7/2013Q114($0.20)($0.21)$79.67 million$76.60 millionViewListenView Earnings Details
8/27/2013Q4 2013($0.20)($0.20)$82.29 million$84.90 millionViewListenView Earnings Details
5/7/2013Q3 2013($0.22)($0.37)$77.97 million$70.55 millionViewListenView Earnings Details
2/6/2013Q2 2013($0.33)($0.30)$74.23 million$77.80 millionViewListenView Earnings Details
11/7/2012Q113($0.22)($0.23)$85.41 million$83.00 millionViewN/AView Earnings Details
9/6/2012Q412($0.12)($0.20)$106.92 million$100.50 millionViewN/AView Earnings Details
5/8/2012($0.14)($0.21)ViewN/AView Earnings Details
11/8/2011($0.29)($0.38)ViewN/AView Earnings Details
9/19/2011$0.02($0.40)ViewN/AView Earnings Details
5/5/2011$0.04($0.02)ViewN/AView Earnings Details
1/27/2011($0.01)$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Accuray (NASDAQ:ARAY) Earnings Estimates

2017 EPS Consensus Estimate: ($0.12)
2018 EPS Consensus Estimate: ($0.14)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.10)($0.10)($0.10)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171$0.02$0.02$0.02
Q4 20171$0.02$0.02$0.02
Q1 20181($0.04)($0.04)($0.04)
Q2 20181($0.10)($0.10)($0.10)
Q3 20181($0.03)($0.03)($0.03)
Q4 20181$0.03$0.03$0.03
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Accuray (NASDAQ:ARAY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Accuray (NASDAQ ARAY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 78.86%
Insider Trades by Quarter for Accuray (NASDAQ:ARAY)
Insider Trades by Quarter for Accuray (NASDAQ:ARAY)

Accuray (NASDAQ ARAY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Alaleh NouriSVPSell2,166$4.86$10,526.76View SEC Filing  
12/1/2017Joshua LevineCEOSell17,093$4.86$83,071.98View SEC Filing  
12/1/2017Kevin WatersCFOSell7,154$5.06$36,199.24View SEC Filing  
10/4/2017Kelly LondyCOOSell99,136$4.24$420,336.64View SEC Filing  
11/9/2015Joshua LevineCEOBuy50,000$7.12$356,000.00View SEC Filing  
2/2/2015Alaleh NouriSVPSell5,164$7.38$38,110.32View SEC Filing  
11/30/2014Alaleh NouriSVPSell268$6.62$1,774.16View SEC Filing  
11/30/2014Kelly LondyEVPSell2,273$6.62$15,047.26View SEC Filing  
11/3/2014Joshua LevineCEOBuy100,000$6.34$634,000.00View SEC Filing  
5/6/2014Joshua LevineCEOBuy50,000$8.15$407,500.00View SEC Filing  
2/4/2014Richard PettingillDirectorBuy9,795$10.33$101,182.35View SEC Filing  
12/4/2013Jack GoldsteinDirectorSell7,000$7.70$53,900.00View SEC Filing  
12/3/2013Elizabeth DavilaDirectorSell8,000$7.74$61,920.00View SEC Filing  
9/4/2013Darren J MillikenSVPSell11,002$6.53$71,843.06View SEC Filing  
3/5/2013Dennis L WingerDirectorBuy20,000$4.30$86,000.00View SEC Filing  
2/13/2013Joshua LevineCEOBuy100,000$4.38$438,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Accuray (NASDAQ ARAY) News Headlines

Source:
DateHeadline
ETFs with exposure to Accuray, Inc. : December 11, 2017ETFs with exposure to Accuray, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:13 PM
Head-To-Head Comparison: Hologic (HOLX) versus Accuray (ARAY)Head-To-Head Comparison: Hologic (HOLX) versus Accuray (ARAY)
www.americanbankingnews.com - December 5 at 11:36 PM
Analyzing Accuray (ARAY) & Accelerate Diagnostics (AXDX)Analyzing Accuray (ARAY) & Accelerate Diagnostics (AXDX)
www.americanbankingnews.com - December 4 at 9:30 PM
 Analysts Expect Accuray Incorporated (ARAY) Will Announce Quarterly Sales of $91.29 Million Analysts Expect Accuray Incorporated (ARAY) Will Announce Quarterly Sales of $91.29 Million
www.americanbankingnews.com - December 4 at 6:56 AM
Reviewing Accuray (ARAY) & GenMark Diagnostics (GNMK)Reviewing Accuray (ARAY) & GenMark Diagnostics (GNMK)
www.americanbankingnews.com - December 2 at 1:30 AM
Accuray Incorporated (ARAY) SVP Sells $10,526.76 in StockAccuray Incorporated (ARAY) SVP Sells $10,526.76 in Stock
www.americanbankingnews.com - December 1 at 11:28 PM
Accuray Incorporated (ARAY) CFO Sells $36,199.24 in StockAccuray Incorporated (ARAY) CFO Sells $36,199.24 in Stock
www.americanbankingnews.com - December 1 at 10:50 PM
Insider Selling: Accuray Incorporated (ARAY) CEO Sells 17,093 Shares of StockInsider Selling: Accuray Incorporated (ARAY) CEO Sells 17,093 Shares of Stock
www.americanbankingnews.com - December 1 at 10:28 PM
ETFs with exposure to Accuray, Inc. : November 30, 2017ETFs with exposure to Accuray, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 3:15 PM
Accuray (ARAY) Now Covered by Lake Street CapitalAccuray (ARAY) Now Covered by Lake Street Capital
www.americanbankingnews.com - November 30 at 9:43 AM
Can Accuray Build Some Momentum? - Seeking AlphaCan Accuray Build Some Momentum? - Seeking Alpha
seekingalpha.com - November 30 at 5:17 AM
Traders Buy Large Volume of Call Options on Accuray (ARAY)Traders Buy Large Volume of Call Options on Accuray (ARAY)
www.americanbankingnews.com - November 23 at 1:04 AM
New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - November 22 at 4:38 PM
ETFs with exposure to Accuray, Inc. : November 20, 2017ETFs with exposure to Accuray, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 5:24 PM
Accuray Incorporated (ARAY) Receives Consensus Rating of "Hold" from AnalystsAccuray Incorporated (ARAY) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 19 at 8:30 AM
Accuray Incorporated (ARAY) Expected to Post Quarterly Sales of $91.29 MillionAccuray Incorporated (ARAY) Expected to Post Quarterly Sales of $91.29 Million
www.americanbankingnews.com - November 16 at 8:38 PM
 Analysts Anticipate Accuray Incorporated (ARAY) to Post -$0.10 Earnings Per Share Analysts Anticipate Accuray Incorporated (ARAY) to Post -$0.10 Earnings Per Share
www.americanbankingnews.com - November 14 at 3:32 AM
Accuray Military Veterans Support U.S. Veteran CommunityAccuray Military Veterans Support U.S. Veteran Community
finance.yahoo.com - November 8 at 6:09 PM
ETFs with exposure to Accuray, Inc. : November 8, 2017ETFs with exposure to Accuray, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 6:09 PM
Accuray, Inc. :ARAY-US: Earnings Analysis: Q1, 2018 By the Numbers : November 7, 2017Accuray, Inc. :ARAY-US: Earnings Analysis: Q1, 2018 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 5:45 PM
Accuray (ARAY) and Cytosorbents Corporation (CTSO) Critical ContrastAccuray (ARAY) and Cytosorbents Corporation (CTSO) Critical Contrast
www.americanbankingnews.com - November 7 at 2:26 PM
Financial Comparison: Viveve Medical (VIVE) vs. Accuray (ARAY)Financial Comparison: Viveve Medical (VIVE) vs. Accuray (ARAY)
www.americanbankingnews.com - November 4 at 1:40 AM
Accuray (ARAY) and Its Peers Financial ContrastAccuray (ARAY) and Its Peers Financial Contrast
www.americanbankingnews.com - November 1 at 11:10 PM
Brokers Issue Forecasts for Accuray Incorporateds Q2 2018 Earnings (ARAY)Brokers Issue Forecasts for Accuray Incorporated's Q2 2018 Earnings (ARAY)
www.americanbankingnews.com - October 27 at 4:32 PM
$91.29 Million in Sales Expected for Accuray Incorporated (ARAY) This Quarter$91.29 Million in Sales Expected for Accuray Incorporated (ARAY) This Quarter
www.americanbankingnews.com - October 26 at 2:09 PM
Treatment Planning for the CyberKnife® System Now Up to 40% FasterTreatment Planning for the CyberKnife® System Now Up to 40% Faster
finance.yahoo.com - October 26 at 10:21 AM
Accurays (ARAY) Q1 Loss in Line, Revenues Beat Estimates - NasdaqAccuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates - Nasdaq
www.nasdaq.com - October 25 at 10:11 PM
Accuray Incorporated (ARAY) Rating Lowered to Hold at Zacks Investment ResearchAccuray Incorporated (ARAY) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 25 at 8:32 PM
Accurays (ARAY) Q1 Loss in Line, Revenues Beat EstimatesAccuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates
finance.yahoo.com - October 25 at 5:08 PM
Edited Transcript of ARAY earnings conference call or presentation 24-Oct-17 8:30pm GMTEdited Transcript of ARAY earnings conference call or presentation 24-Oct-17 8:30pm GMT
finance.yahoo.com - October 25 at 5:08 PM
ETFs with exposure to Accuray, Inc. : October 25, 2017ETFs with exposure to Accuray, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 5:08 PM
AT&T, Dr Pepper Snapple and Chipotle tumble; Accuray risesAT&T, Dr Pepper Snapple and Chipotle tumble; Accuray rises
finance.yahoo.com - October 25 at 5:08 PM
Accuray Incorporated (ARAY) Given Consensus Rating of "Hold" by BrokeragesAccuray Incorporated (ARAY) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 25 at 9:16 AM
Accurays (ARAY) CEO Joshua Levine on Q1 2018 Results - Earnings Call TranscriptAccuray's (ARAY) CEO Joshua Levine on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - October 24 at 10:50 PM
Accuray Incorporated to Host Earnings CallAccuray Incorporated to Host Earnings Call
finance.yahoo.com - October 24 at 5:48 PM
Accuray Incorporated to Host Earnings CallAccuray Incorporated to Host Earnings Call
finance.yahoo.com - October 24 at 5:48 PM
Accuray Generated $55.6 Million in First Quarter Gross Orders; Revenue Increased 5 Percent Year over YearAccuray Generated $55.6 Million in First Quarter Gross Orders; Revenue Increased 5 Percent Year over Year
finance.yahoo.com - October 24 at 5:48 PM
Accuray Generated $55.6 Million in First Quarter Gross Orders; Revenue Increased 5 Percent Year over YearAccuray Generated $55.6 Million in First Quarter Gross Orders; Revenue Increased 5 Percent Year over Year
finance.yahoo.com - October 24 at 5:48 PM
Accuray reports 1Q lossAccuray reports 1Q loss
finance.yahoo.com - October 24 at 5:48 PM
Accuray reports 1Q lossAccuray reports 1Q loss
finance.yahoo.com - October 24 at 5:48 PM
Accuray Incorporated (ARAY) Posts  Earnings ResultsAccuray Incorporated (ARAY) Posts Earnings Results
www.americanbankingnews.com - October 24 at 5:46 PM
Accuray Incorporated (ARAY) Stock Rating Upgraded by Zacks Investment ResearchAccuray Incorporated (ARAY) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 24 at 3:00 PM
Accuray: Court Of Appeal Confirms CHU Tours Decision - Quick FactsAccuray: Court Of Appeal Confirms CHU Tours Decision - Quick Facts
www.nasdaq.com - October 19 at 4:34 PM
Accuray (ARAY) Reports European Court of Appeal Rejects Varians (VAR) Attempt to Reverse Customer Purchase of Accuray TomoTherapy SystemAccuray (ARAY) Reports European Court of Appeal Rejects Varian's (VAR) Attempt to Reverse Customer Purchase of Accuray TomoTherapy System
www.streetinsider.com - October 19 at 4:34 PM
European Court of Appeal Rejects Varians Attempt to Reverse Customer Purchase of Accuray TomoTherapy® SystemEuropean Court of Appeal Rejects Varian's Attempt to Reverse Customer Purchase of Accuray TomoTherapy® System
finance.yahoo.com - October 19 at 4:34 PM
Mid-Day Market Update: Syntel Surges After Strong Q3 Results; Impax Laboratories Shares DropMid-Day Market Update: Syntel Surges After Strong Q3 Results; Impax Laboratories Shares Drop
www.nasdaq.com - October 17 at 4:50 PM
Accuray Incorporated (ARAY) Scheduled to Post Quarterly Earnings on TuesdayAccuray Incorporated (ARAY) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - October 17 at 6:26 AM
Accuray, Inc. breached its 50 day moving average in a Bearish Manner : ARAY-US : October 16, 2017Accuray, Inc. breached its 50 day moving average in a Bearish Manner : ARAY-US : October 16, 2017
finance.yahoo.com - October 16 at 4:52 PM
Critical Contrast: Accuray (ARAY) and Its RivalsCritical Contrast: Accuray (ARAY) and Its Rivals
www.americanbankingnews.com - October 14 at 2:20 AM
Contrasting ABIOMED (ABMD) and Accuray (ARAY)Contrasting ABIOMED (ABMD) and Accuray (ARAY)
www.americanbankingnews.com - October 12 at 10:36 AM

SEC Filings

Accuray (NASDAQ:ARAY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Accuray (NASDAQ:ARAY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Accuray (NASDAQ ARAY) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.